Henning Steinhagen

Henning joined Epidarex in 2019. He is a senior executive with 20 years of experience and track record in the Pharma, Biotech and CRO/CDMO industries. His experience spans multiple therapeutic areas and all phase of research and early development.

Prior to joining Epidarex, Henning served as President of Research and Development (R&D) at Aptuit. As an operational leader, he led significant growth and transformation of the integrated ex-GSK site in Verona, Italy into a profitable organization. He was a key player in the $300 million sale of Aptuit to Evotec in 2017.

Prior to Aptuit, Henning was Senior Vice President and Head of Global Drug Discovery at Grünenthal in Germany. His accomplishments include the build-up of the immuno-inflammation area as well as advancing Grünenthal’s CNS portfolio, including executing several R&D partnerships and licensing deals. Before joining Grünenthal, Henning served as a Director of Medicinal Chemistry at Sanofi-Aventis. He started his career at Bayer Pharma.

Adding on to his role as Venture Partner at Epidarex, Henning co-founded and leads Epidarex Exeed Ltd., the Epidarex therapeutic discovery engine as CEO and member of the Board of Director since end of 2019.

Henning also serves on the Board of Directors of Caldan Therapeutics Ltd. as well as senior advisor for several organizations including the Osthus Group and tesa Labtec. He is a member and former chair of the board of MedLife, a not-for-profit MedTech association.

Henning holds a Ph.D. in Chemistry from the University of Heidelberg with a degree in Molecular Genetics. His academic experiences include post-doctoral study with Nobel laureate Prof. E.J. Corey at Harvard University as well as an Adjunct Professorship at Trinity College Dublin, Ireland. He holds an executive MBA from IMD in Lausanne, Switzerland.